News Releases

Pfenex To Present at the JMP Securities Life Sciences Conference 2015

SAN DIEGO, June 16, 2015 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics including high value and difficult to manufacture proteins, announced today that Bertrand C. Liang, chief executive officer of Pfenex will be presenting at the JMP Securities Life Sciences Conference 2015 at the St. Regis New York, 2 East 55th Street, New York on June 24th at 3 pm ET. To access the live webcast and replay, please log on to www.pfenex.com or access the link directly at http://wsw.com/webcast/jmp27/pfnx.

Pfenex logo

Pfenex has used, and intends to continue to use, its Investor Relations website (http://pfenex.investorroom.com), as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit (http://pfenex.investorroom.com).

About Pfenex Inc.
Pfenex Inc. is a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics and high-value and difficult to manufacture proteins. The company's lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab), for the potential treatment of patients with retinal diseases. Pfenex has leveraged its Pfēnex Expression Technology® platform to build a pipeline of product candidates and preclinical products under development including other biosimilars, as well as vaccines, generics and next generation biologics.  

Logo - http://photos.prnewswire.com/prnh/20140715/127348

 

SOURCE Pfenex Inc.

For further information: Paul Wagner, Ph.D., Chief Financial Officer, (858) 352-4333, pwagner@pfenex.com